Literature DB >> 24743915

The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.

Shigeru Yamaguchi1, Kenji Hirata, Hiroyuki Kobayashi, Tohru Shiga, Osamu Manabe, Kentaro Kobayashi, Hiroaki Motegi, Shunsuke Terasaka, Kiyohiro Houkin.   

Abstract

OBJECTIVE: (18)F-FDG PET has become one of the most important methods for studying malignant lymphoma, but its diagnostic role for primary central nervous system lymphoma (PCNSL) has not been established. The aim of this study was to determine the appropriate cut-off values of FDG uptake and to investigate how corticosteroid administration influences PCNSL.
METHODS: We retrospectively reviewed 82 patients with contrast-enhanced brain tumors who underwent an FDG PET scan at onset, including 19 PCNSLs. FDG uptake of the lesion was assessed by the maximum standardized uptake value (SUVmax) and the ratio of tumor to normal contralateral cortex activity (T/N ratio). Receiver operating characteristic (ROC) curves were generated from the SUVmax and T/N ratios. To investigate the influence of corticosteroid application before a FDG PET scan, we evaluated the association between the FDG uptake of the lesion and the cumulative dose of corticosteroid administration on 13 PCNSL patients who had received steroid treatment before an FDG PET examination.
RESULTS: The mean FDG SUVmax and T/N ratio of PCNSLs were 22.6 and 2.79, respectively, and these values were significantly higher than those of the other malignant brain tumors. ROC analysis indicated that the evaluation of FDG uptake using the T/N ratio was more reliable than the SUVmax with respect to the differential diagnosis. When PCNSL patients went without steroid application before FDG PET, the accuracy of the T/N ratio with a cut-off point of 2.0 was 91.1%, the sensitivity was 94.7%, and the specificity was 87.3%. Although there are no significant differences in the FDG T/N ratio for PCNSL patients with or without steroid treatment, a negative correlation was found between the T/N ratio and cumulative dose of corticosteroid before PET study (r = -0.71, p = 0.032).
CONCLUSIONS: We concluded that the T/N ratio was superior to SUVmax for FDG uptake assessment as for distinguishing PCNSLs from other malignant brain tumors; the appropriate T/N ratio cut-off point was 2.0. In addition, FDG uptake could be influenced by cumulative doses of corticosteroid before a PET scan, and thus this fact should be taken into consideration when evaluating FDG PET for PCNSL diagnosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24743915     DOI: 10.1007/s12149-014-0851-8

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  10 in total

1.  18F-FDG PET/CT in primary brain lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Mattia Bertoli; Raffaele Giubbini; Francesco Bertagna
Journal:  J Neurooncol       Date:  2017-11-17       Impact factor: 4.130

2.  Usefulness of dual isotope 123I-IMP and 201Tl SPECT for the diagnosis of primary central nervous system lymphoma and glioblastoma.

Authors:  Sho Osawa; Masahiko Tosaka; Keishi Horiguchi; Azusa Tokue; Tetsuya Higuchi; Yoshito Tsushima; Yuhei Yoshimoto
Journal:  Int J Clin Oncol       Date:  2022-05-13       Impact factor: 3.850

3.  Differential diagnosis of posterior fossa brain tumors: Multiple discriminant analysis of Tl-SPECT and FDG-PET.

Authors:  Moritaka Yamauchi; Tomohisa Okada; Tsutomu Okada; Akira Yamamoto; Yasutaka Fushimi; Yoshiki Arakawa; Susumu Miyamoto; Kaori Togashi
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

4.  Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients.

Authors:  Rudy Birsen; Estelle Blanc; Lise Willems; Barbara Burroni; Marielle Legoff; Emmanuelle Le Ray; Sylvain Pilorge; Sawsen Salah; Aude Quentin; Benedicte Deau; Patricia Franchi; Marguerite Vignon; Laurence Mabille; Charles Nguyen; Yioula Kirova; Pascale Varlet; Myriam Edjlali; Edouard Dezamis; Khê Hoang-Xuan; Carole Soussain; Caroline Houillier; Diane Damotte; Johan Pallud; Didier Bouscary; Jerome Tamburini
Journal:  Oncotarget       Date:  2018-03-30

5.  Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma.

Authors:  Meetakshi Gupta; Tejpal Gupta; Nilendu Purandare; Venkatesh Rangarajan; Ameya Puranik; Aliasgar Moiyadi; Prakash Shetty; Sridhar Epari; Ayushi Sahay; Abhishek Mahajan; Amit Janu; Bhausaheb Bagal; Hari Menon; Sadhana Kannan; Rahul Krishnatry; Goda Jayant Sastri; Rakesh Jalali
Journal:  CNS Oncol       Date:  2019-11-29

Review 6.  Role of Positron Emission Tomography in Primary Central Nervous System Lymphoma.

Authors:  Laura Rozenblum; Caroline Houillier; Carole Soussain; Marc Bertaux; Sylvain Choquet; Damien Galanaud; Khê Hoang-Xuan; Aurélie Kas
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

7.  A rare case of nonenhancing primary central nervous system lymphoma mimic multiple sclerosis.

Authors:  Hai Chen; Huiqing Dong
Journal:  Neurosciences (Riyadh)       Date:  2015-10       Impact factor: 0.906

Review 8.  Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.

Authors:  Yaru Zou; Jianjing Tong; Haiyan Leng; Jingwei Jiang; Meng Pan; Zi Chen
Journal:  Oncotarget       Date:  2017-06-20

Review 9.  Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring.

Authors:  C Chiavazza; A Pellerino; F Ferrio; A Cistaro; R Soffietti; R Rudà
Journal:  Biomed Res Int       Date:  2018-06-21       Impact factor: 3.411

10.  18F-FDG-PET-based radiomics features to distinguish primary central nervous system lymphoma from glioblastoma.

Authors:  Ziren Kong; Chendan Jiang; Ruizhe Zhu; Shi Feng; Yaning Wang; Jiatong Li; Wenlin Chen; Penghao Liu; Dachun Zhao; Wenbin Ma; Yu Wang; Xin Cheng
Journal:  Neuroimage Clin       Date:  2019-06-27       Impact factor: 4.881

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.